Halloween has come and gone in the US, and Americans are now gearing up for Thanksgiving and Christmas. But before the holiday season could get underway, the country went through a major political event with far-reaching implications: the midterm elections.As…
Maruho is expanding its licensing collaboration with Taiwan’s Orient EuroPharma for its primary axillary hyperhidrosis treatment Rapifort Wipes (glycopyrronium tosilate hydrate) to cover 10 ASEAN countries. Under a new agreement announced on October 1, Orient will receive the development and…
To read the full story
Related Article
- Maruho Out-Licenses Rapifort to Taiwan’s Orient EuroPharma
January 23, 2026
- Maruho Gets Asia Rights to Hyperhidrosis Wipe Drug
September 8, 2023
BUSINESS
- Nipro Eyes 50-60 Stemirac Treatment Sites across Japan after Full Nod
November 20, 2026
- AstraZeneca’s Etcamah to Hit Japan Market on Nov. 27
November 20, 2026
- Japan Drug Makers’ Sales Seen Dipping in FY2026 on Co-Marketing Exits
November 20, 2026
- J&J’s Icotyde Could Broaden Psoriasis Treatment Options: Expert
November 20, 2026
- Nippon Kayaku to Acquire AstraZeneca’s Zoladex on Dec. 16
November 20, 2026





